{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bhuiyan TR"],"funding":["NIAID NIH HHS","FIC NIH HHS"],"pagination":["198-203"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8809641"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2"],"pubmed_abstract":["<h4>Design</h4>A cross-sectional study was conducted amongst household members in 32 districts of Bangladesh to build knowledge about disease epidemiology and seroepidemiology of coronavirus disease 2019 (COVID-19).<h4>Objective</h4>Antibody responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were assessed in people between April and October 2020.<h4>Results</h4>The national seroprevalence rates of immunoglobulin G (IgG) and IgM were estimated to be 30.4% and 39.7%, respectively. In Dhaka, the seroprevalence of IgG was 35.4% in non-slum areas and 63.5% in slum areas. In areas outside of Dhaka, the seroprevalence of IgG was 37.5% in urban areas and 28.7% in rural areas. Between April and October 2020, the highest seroprevalence rate (57% for IgG and 64% for IgM) was observed in August. IgM antibody was more prevalent in younger participants, while older participants had more frequent IgG seropositivity. Follow-up specimens from patients with COVID-19 and their household members suggested that both IgG and IgM seropositivity increased significantly at day 14 and day 28 compared with day 1 after enrolment. <i>Conclusions</i>: SARS-CoV-2 had spread extensively in Bangladesh by October 2020. This highlights the importance of monitoring seroprevalence data, particularly with the emergence of new SARS-CoV-2 variants over time."],"journal":["IJID regions"],"pubmed_title":["Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection."],"pmcid":["PMC8809641"],"funding_grant_id":["R01 AI130378","K43 TW010362"],"pubmed_authors":["Charles RC","Arifeen SE","Qadri F","Bablu AR","Alamgir ASM","Ferdous J","Rahman SIA","Hossain K","Shirin T","Calderwood SB","Akhtar M","Flora MS","Nazneen A","Tony SR","LaRocque RC","Bhuiyan TR","Akter A","Khaton F","Harris JB","Rahman M","Sumon SA","Banik KC","Banu S","Ryan ET","Chakraborty N"],"additional_accession":[]},"is_claimable":false,"name":"Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection.","description":"<h4>Design</h4>A cross-sectional study was conducted amongst household members in 32 districts of Bangladesh to build knowledge about disease epidemiology and seroepidemiology of coronavirus disease 2019 (COVID-19).<h4>Objective</h4>Antibody responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were assessed in people between April and October 2020.<h4>Results</h4>The national seroprevalence rates of immunoglobulin G (IgG) and IgM were estimated to be 30.4% and 39.7%, respectively. In Dhaka, the seroprevalence of IgG was 35.4% in non-slum areas and 63.5% in slum areas. In areas outside of Dhaka, the seroprevalence of IgG was 37.5% in urban areas and 28.7% in rural areas. Between April and October 2020, the highest seroprevalence rate (57% for IgG and 64% for IgM) was observed in August. IgM antibody was more prevalent in younger participants, while older participants had more frequent IgG seropositivity. Follow-up specimens from patients with COVID-19 and their household members suggested that both IgG and IgM seropositivity increased significantly at day 14 and day 28 compared with day 1 after enrolment. <i>Conclusions</i>: SARS-CoV-2 had spread extensively in Bangladesh by October 2020. This highlights the importance of monitoring seroprevalence data, particularly with the emergence of new SARS-CoV-2 variants over time.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-18T12:19:23.713Z","creation":"2025-04-06T21:48:50.771Z"},"accession":"S-EPMC8809641","cross_references":{"pubmed":["35721426"],"doi":["10.1016/j.ijregi.2022.01.013"]}}